臨床研究等提出・公開システム

Date of registration	Mar. 22, 2017
Last modified on	Jan. 14, 2021
Trial ID	jRCT2080223484

Scientific Title	-
Public Title	-

Contact for Scientific Queries	Name
	Contact Name for Scientific Queries	-
	Address	-
	Phone Number	+81-120-003-293
	E-mail Address	-

Contact for Public Queries	Name
	Contact Name for Public Queries	-
	Address	-
	Phone Number	+81-120-003-293
	E-mail Address	-

Recruitment Status	completed

Date of First Enrolment		April. 13, 2017
Target Sample Size		67
Study Type		Interventional
Study Design	Study Design	-
Study Design	Objective	treatment purpose
Phase		1
Key inclusion & exclusion criteria	Inclusion Criteria	-
	Exclusion Criteria	-
	Minimum Age	18age old over
	Maximum Age	No limit
	Gender	Both
Health Condition or Problem Studied		-
Intervention(s)		investigational material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : - control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : -
Health Condition(s) Keyword
Intervention(s) Keyword
Health Condition(s) Code
Intervention(s) Code
Primary Outcome		safety -
Secondary Outcome		efficacy pharmacokinetics pharmacodynamics -

Primary Sponsor	-
Secondary Sponsor	-

Name of Funding Organization	-
Name of Research Funding	-

Name of IRB	-
Address of IRB	-
Phone Number of IRB	-
E-mail Address of IRB	-
Status of IRB Review	approved
Date of Approval by IRB	April. 13, 2017

Secondary ID No.	JapicCTI-173539
Name of Other Registries

Countries / Regions of Recruitment	Japan/Asia except Japan/North America/Europe/Oceania

History of Changes

No	Publication date
3	Jan. 14, 2021	(this page)	Changes
2	July. 12, 2017	Detail	Changes
1	Mar. 22, 2017	Detail

List of change history